



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals,  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Senior Production Editor**  
Malcolm Smith  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](http://support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/productservices/  
rights-and-licensing/](http://bmj.com/company/productservices/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** *International Journal of Gynecological Cancer* is owned by the International Gynecologic Cancer Society (IGCS) and the European Society of Gynaecological Oncology (ESGO). The owners grant editorial freedom to the Editor of *IJGC*. *IJGC* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

*IJGC* is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the Societies or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of *IJGC* or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2019 ICGS and ESGO. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior permission The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Editorial

- 225** Pre-operative evaluation in advanced ovarian cancer: is ultrasound ready to replace computed tomography?  
*D Verri*

## Original Article

- 227** Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography  
*J L Alcázar, M Caparros, M Arraiza, J Á Mínguez, S Guerrero, L Chiva, M Jurado*

## Preinvasive Disease

- 234** Role of HPV genotyping in risk assessment among cytology diagnosis categories: analysis of 4562 cases with cytology–HPV cotesting and follow-up biopsies  
*Y Ge, P Christensen, E Luna, D Arnylagos, J Xu, M R Schwartz, D R Mody*

- 242** Association of human papillomavirus and bacterial vaginosis with increased risk of high-grade squamous intraepithelial cervical lesions  
*T T Suehiro, N Malaguti, E Damke, N S Uchimura, F Gimenes, R P Souza, V R Sela da Silva, M E Lopes Consolaro*

- 250** Persuasive messaging for human papillomavirus vaccination by adolescent providers in a five-country multi-site study  
*J Rwamwejo, S Ramos, K Morgan, K Richter, C J Kim, M Peris, J S Smith*

## Cervical Cancer

- 257** Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer  
*N Horeweg, C L Creutzberg, E C Rijkmans, M S Laman, L A Velema, V L M A Coen, T C Stam, E M Kerkhof, J R Kroep, C D de Kroon, R A Nout*

- 266** The role of positron emission tomography in the selection of patients for salvage hysterectomy following chemoradiotherapy for locally advanced cervical cancer  
*C Rajasooriyar, M-Y Lin, R Kalra, A Lim, K Narayan*

- 272** Capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study  
*M Giuseppa, L Stefano, S Ilaria, T Elisa, L Domenica*

## Endometrial Cancer

- 277** Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma  
*M Osakabe, D Fukagawa, C Sato, R Sugimoto, N Uesugi, K Ishida, H Itamochi, T Sugiyama, T Sugai*

- 282** Does lymphadenectomy improve survival in patients with intermediate risk endometrial cancer? A multicentric study from the FRANCOGYN Research Group  
*L Bougherara, H Azaïs, H Béhal, G Canlorbe, M Ballester, S Bendifallah, C Coutant, V Lavoue, L Ouldamer, O Graesslin, C Touboul, J P Estevez, P Collinet*

- 290** The association between histological subtype of a first primary endometrial cancer and second cancer risk  
*J Rhoades, M H Vetter, J L Fisher, D E Cohn, R Salani, A S Felix*

- 299** Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical comorbidities precluding standard surgical procedures: a systematic review  
*A-J Kruse, H G ter Brugge, H H de Haan, H W Van Eyndhoven, H W Nijman*

- 305** DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I–III  
*T Svanvik, U Strömberg, E Holmberg, J Marckiewicz, K Sundfeldt*

- 312** Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, and incidence and potential risk factors: a single institution experience  
*L Volpi, G Sozzi, V A Capozzi, M Ricco', C Merisio, M Di Serio, V Chiantera, R Berretta*

- 320** A novel prediction method for lymph node involvement in endometrial cancer: machine learning  
*E Günakan, S Atan, A N Haberal, I A Küçükylidiz, E Gökçe, A Ayhan*
- 
- Ovarian Cancer**
- 325** Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients  
*S E Rivkin, J Moon, D S Iriarte, E Bailey, H L Sloan, G E Goodman, A E BonDurant, D Velijovich, T Wahl, P Jiang, C A Shah, C Drescher, M F Fer, H G Kaplan, E D Ellis*
- 334** Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer  
*L Y Li, S W Kim, E J Nam, J Y Lee, S Kim, Y T Kim*
- 341** Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer  
*R D Morgan, A R Clamp, C Zhou, G Saunders, N Mescallado, R Welch, C Mitchell, J Hasan, G C Jayson*
- 346** *TP53* mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses  
*V Mandilaras, S Garg, M Cabanero, Q Tan, C Pastrello, J Burnier, K Karakasis, L Wang, N C Dhani, M O Butler, P L Bedard, L L Siu, B Clarke, P A Shaw, T Stockley, I Jurisica, A M Oza, S Lheureux*
- 353** Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results  
*S Böhm, N Le, M Lockley, E Brockebank, A Faruqi, I Said, A Jeyarajah, R Wuntakal, B Giles, N Singh*
- 357** Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer  
*J T Veneris, L Huang, J E Churpek, S D Conzen, G F Fleming*
- 365** Patterns of care and outcomes for women with uterine cancer and ovarian metastases  
*N L Jones, Y Huang, S Chatterjee, A I Tergas, W M Burke, J Y Hou, I Deutsch, C V Ananth, A I Neugut, D L Hershman, J D Wright*
- 377** Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study  
*V Lago, P Bello, B Montero, L Matute, P Padilla-Iserte, S Lopez, M Agudelo, S Domingo*
- 382** Predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy for ovarian peritoneal carcinomatosis  
*M A Angeles, F Quenet, P Vieille, L Gladieff, J Ruiz, M Picard, F Migliorelli, L Chaltiel, C Martínez-Gómez, A Martinez, G Ferron*
- 392** Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer  
*M Timmermans, G S Sonke, K K Van de Vijver, P B Ottevanger, H W Nijman, M A van der Aa, R F P M Kruiwagen*
- 398** Are omentectomy and lymphadenectomy necessary in patients with apparently early-stage malignant ovarian germ cell tumors?  
*B Qin, W Xu, Y Li*
- 
- Review Articles**
- 404** Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article  
*C Maggen, M van Gerven, K Van Calsteren, T Vandenbroucke, F Amant*

- 417** A report on the Marrakech International Women's Cancer Days: dialogs and implications  
*S Nasser, J Berek, A Ullrich, L Giordano, J Sehouli*

- 422** Reviewing vulvar Paget's disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE  
*G Mantovani, A Fagotti, M Franchi, G Scambia, G Garganese*

---

### Clinical Trial

- 430** Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer  
*K N Moore, S Pignata, on behalf of the IMagyn050 Steering Committee*

---

### Case Study

- 434** Conservative management of cervical cancer in pregnancy  
*P T Ramirez, N R Abu-Rustum, E Euscher*

---

### Corners of the World

- 439** Improving the quality of care in a public hospital in Guatemala  
*E E Estrada*

---

### Video Articles

- 441** The anatomical structure of the paravesico-vaginal space, a novel landmark for nerve-sparing radical hysterectomy  
*S Yin, S-N Ma, R-Y Zang*
- 442** How to perform a laparoscopic pelvic sentinel lymph node dissection using near-infrared fluorescence with indocyanine green in gynecological cancers  
*E Vésale, H Azaïs, J Belghiti, M Nikpayam, C Uzan, G Canlorbe*
- 443** Inguino-abdominal combined approach for laterally extended pelvic resection: a step by step procedure  
*G Vizzielli, E Perrone, A Gioè, G Tinelli, G Scambia*